Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Summary

The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)

Timeline

Start

2025-01-01

Primary completion

2027-01-01

Completion

2029-01-01

Drugs

Indications